Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro

被引:2
|
作者
Zhang, Yaqing [1 ,2 ]
Lv, Qi [1 ,2 ]
Qi, Feifei [1 ,2 ]
Li, Fengdi [1 ,2 ]
Deng, Ran [1 ,2 ]
Liang, Xujian [1 ,2 ]
Liu, Mingya [1 ,2 ]
Yan, Yiwei [1 ,2 ]
Bao, Linlin [1 ,2 ,3 ,4 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Lab Anim Sci, Beijing Key Lab Anim Models Emerging & Reemerging, NHC Key Lab Human Dis Comparat Med, Beijing, Peoples R China
[2] Natl Ctr Technol Innovat Anim Model, Beijing, Peoples R China
[3] Chinese Acad Med Sci CAMS, Inst Lab Anim Sci, Beijing, Peoples R China
[4] Peking Union Med Coll PUMC, Comparat Med Ctr, Beijing, Peoples R China
关键词
cross-neutralize; Omicron; replication; SARS-CoV-2;
D O I
10.1002/ame2.12302
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
BackgroundNew Omicron subvariants are emerging rapidly from BA.1 to BA.4 and BA.5. Their pathogenicity has changed from that of wild-type (WH-09) and Omicron variants have over time become globally dominant. The spike proteins of BA.4 and BA.5 that serve as the target for vaccine-induced neutralizing antibodies have also changed compared to the previous subvariants, which is likely to cause immune escape and the reduction of the protective effect of the vaccine. Our study addresses the above issues and provides a basis for formulating relevant prevention and control strategies. MethodsWe collected cellular supernatant and cell lysates and measured the viral titers, viral RNA loads, and E subgenomic RNA (E sgRNA) loads in different Omicron subvariants grown in Vero E6 cells, using WH-09 and Delta variants as a reference. Additionally, we evaluated the in vitro neutralizing activity of different Omicron subvariants and compared it to the WH-09 and Delta variants using macaque sera with different types of immunity. ResultsAs the SARS-CoV-2 evolved into Omicron BA.1, the replication ability in vitro began to decrease. Then with the emergence of new subvariants, the replication ability gradually recovered and became stable in the BA.4 and BA.5 subvariants. In WH-09-inactivated vaccine sera, geometric mean titers of neutralization antibodies against different Omicron subvariants declined by 3.7 similar to 15.4-fold compared to those against WH-09. In Delta-inactivated vaccine sera, geometric mean titers of neutralization antibodies against Omicron subvariants declined by 3.1 similar to 7.4-fold compared to those against Delta. ConclusionAccording to the findings of this research, the replication efficiency of all Omicron subvariants declined compared with WH-09 and Delta variants, and was lower in BA.1 than in other Omicron subvariants. After two doses of inactivated (WH-09 or Delta) vaccine, cross-neutralizing activities against various Omicron subvariants were seen despite a decline in neutralizing titers.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [41] Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
    Alcantara, Mellissa C. C.
    Higuchi, Yusuke
    Kirita, Yuhei
    Matoba, Satoaki
    Hoshino, Atsushi
    VACCINES, 2023, 11 (03)
  • [42] Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
    Chatterjee, Srijan
    Bhattacharya, Manojit
    Dhama, Kuldeep
    Lee, Sang-Soo
    Chakraborty, Chiranjib
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2023, 32 : 263 - 266
  • [43] Enhanced recombination among Omicron subvariants of SARS-CoV-2 contributes to viral immune escape
    Shiraz, Rishad
    Tripathi, Shashank
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [44] Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
    Anna R. Mäkelä
    Hasan Uğurlu
    Liina Hannula
    Ravi Kant
    Petja Salminen
    Riku Fagerlund
    Sanna Mäki
    Anu Haveri
    Tomas Strandin
    Lauri Kareinen
    Jussi Hepojoki
    Suvi Kuivanen
    Lev Levanov
    Arja Pasternack
    Rauno A. Naves
    Olli Ritvos
    Pamela Österlund
    Tarja Sironen
    Olli Vapalahti
    Anja Kipar
    Juha T. Huiskonen
    Ilona Rissanen
    Kalle Saksela
    Nature Communications, 14
  • [45] Comparison of Four SARS-CoV-2 Neutralization Assays
    Riepler, Lydia
    Roessler, Annika
    Falch, Albert
    Volland, Andre
    Borena, Wegene
    von Laer, Dorothee
    Kimpel, Janine
    VACCINES, 2021, 9 (01) : 1 - 14
  • [46] Detection and isolation of infectious SARS-CoV-2 omicron subvariants collected from residential settings
    Vass, William B.
    Nannu Shankar, Sripriya
    Lednicky, John A.
    Yang, Yang
    Manzanas, Carlos
    Zhang, Yuetong
    Boyette, Jessica
    Chen, Jiayi
    Chen, Yuqiao
    Shirkhani, Amin
    Washeem, Mo
    Fan, Z. Hugh
    Eiguren-Fernandez, Arantzazu
    Jutla, Antarpreet
    Wu, Chang-Yu
    AEROSOL SCIENCE AND TECHNOLOGY, 2023, 57 (11) : 1142 - 1153
  • [47] Systematic analysis of SARS-CoV-2 Omicron subvariants' impact on B and T cell epitopes
    Al Khalaf, Ruba
    Bernasconi, Anna
    Pinoli, Pietro
    PLOS ONE, 2024, 19 (09):
  • [48] Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
    Roessler, Annika
    Knabl, Ludwig
    von Laer, Dorothee
    Kimpel, Janine
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18): : 1764 - 1766
  • [49] Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86
    Lasrado, Ninaad
    Collier, Ai-ris Y.
    Hachmann, Nicole P.
    Miller, Jessica
    Rowe, Marjorie
    Schonberg, Eleanor D.
    Rodrigues, Stefanie L.
    LaPiana, Austin
    Patio, Robert C.
    Anand, Trisha
    Fisher, Jana
    Mazurek, Camille R.
    Guan, Ruoran
    Wagh, Kshitij
    Theiler, James
    Korber, Bette T.
    Barouch, Dan H.
    VACCINE, 2023, 41 (47) : 6904 - 6909
  • [50] Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
    Xia, Hongjie
    Yeung, Jason
    Kalveram, Birte
    Bills, Cody J.
    Chen, John Yun-Chung
    Kurhade, Chaitanya
    Zou, Jing
    Widen, Steven G.
    Mann, Brian R.
    Kondor, Rebecca
    Davis, C. Todd
    Zhou, Bin
    Wentworth, David E.
    Xie, Xuping
    Shi, Pei-Yong
    EMERGING MICROBES & INFECTIONS, 2023, 12 (01)